In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Shares of Biogen were lower Tuesday after the company resolved a dispute with Forward Pharma over its multiple sclerosis drug.
Biogen will pay Forward $1.25 billion.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
Biogen spinoff Bioverativ proved healthy out of the gate, jumping from an open of $40 a share to a close of $47.35.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.